Lilly Receives Positive CHMP Opinion for Emgality

2018-10-17T12:24:24+00:0017/10/2018|Categories: Industry, News|Tags: , , , , |

INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month. TM In June 2018, Lilly announced the intended brand name, Emgality, was conditionally accepted by the U.S. Food and Drug Administration (FDA). Emgality is a humanized monoclonal antibody specifically designed to bind to the calcitonin gene-related peptide (CGRP), blocking its [...]

We and our partners use cookies, to collect browsing data to give you the best online experience and to personalize the content, play multimedia content, interact with social networks and perform browsing analytics. If you continue browsing we understand you accept the use of such technology. For more information visit our cookies policy Find out more

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close